Biotest Aktiengesellschaft (BIO.DE)
EUR 42.6
(0.47%)
EUR 42.6
(0.47%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 684.6 Million EUR | 32.65% |
| 2022 | 516.1 Million EUR | 0.1% |
| 2021 | 515.6 Million EUR | 6.48% |
| 2020 | 484.2 Million EUR | 15.53% |
| 2019 | 419.1 Million EUR | 4.7% |
| 2018 | 400.3 Million EUR | 5.87% |
| 2017 | 378.1 Million EUR | -31.64% |
| 2016 | 553.1 Million EUR | -6.19% |
| 2015 | 589.6 Million EUR | 1.31% |
| 2014 | 582 Million EUR | 16.21% |
| 2013 | 500.8 Million EUR | 13.83% |
| 2012 | 439.96 Million EUR | 4.25% |
| 2011 | 422.02 Million EUR | 2.31% |
| 2010 | 412.48 Million EUR | -6.29% |
| 2009 | 440.19 Million EUR | 4.07% |
| 2008 | 422.95 Million EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | -100.0% |
| 2004 | 217.85 Million EUR | -1.82% |
| 2003 | 221.88 Million EUR | -13.95% |
| 2002 | 257.85 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 215.2 Million EUR | 16.77% |
| 2024 Q2 | 156.8 Million EUR | -27.14% |
| 2023 Q3 | 252.8 Million EUR | 60.0% |
| 2023 Q1 | 117.2 Million EUR | -24.53% |
| 2023 Q2 | 158 Million EUR | 34.81% |
| 2023 Q4 | 184.3 Million EUR | -27.1% |
| 2023 FY | 684.6 Million EUR | 32.65% |
| 2022 Q4 | 155.3 Million EUR | 44.2% |
| 2022 Q3 | 107.7 Million EUR | -21.5% |
| 2022 Q2 | 137.2 Million EUR | 18.38% |
| 2022 Q1 | 115.9 Million EUR | -19.63% |
| 2022 FY | 516.1 Million EUR | 0.1% |
| 2021 FY | 515.6 Million EUR | 6.48% |
| 2021 Q1 | 120 Million EUR | -15.85% |
| 2021 Q2 | 137.8 Million EUR | 14.83% |
| 2021 Q3 | 113.6 Million EUR | -17.56% |
| 2021 Q4 | 144.2 Million EUR | 26.94% |
| 2020 FY | 484.2 Million EUR | 15.53% |
| 2020 Q1 | 97.7 Million EUR | -21.34% |
| 2020 Q2 | 137.1 Million EUR | 40.33% |
| 2020 Q3 | 106.8 Million EUR | -22.1% |
| 2020 Q4 | 142.6 Million EUR | 33.52% |
| 2019 Q1 | 77.5 Million EUR | -29.99% |
| 2019 Q3 | 99.8 Million EUR | -15.14% |
| 2019 Q4 | 124.2 Million EUR | 24.45% |
| 2019 FY | 419.1 Million EUR | 4.7% |
| 2019 Q2 | 117.6 Million EUR | 51.74% |
| 2018 Q2 | 112.8 Million EUR | 28.18% |
| 2018 FY | 400.3 Million EUR | 5.87% |
| 2018 Q1 | 88 Million EUR | 29233.33% |
| 2018 Q3 | 88.9 Million EUR | -21.19% |
| 2018 Q4 | 110.7 Million EUR | 24.52% |
| 2017 Q3 | 130.7 Million EUR | -4.32% |
| 2017 Q2 | 136.6 Million EUR | 23.62% |
| 2017 FY | 378.1 Million EUR | -31.64% |
| 2017 Q4 | 300 Thousand EUR | -99.77% |
| 2017 Q1 | 110.5 Million EUR | 13.33% |
| 2016 Q4 | 97.5 Million EUR | -34.78% |
| 2016 Q2 | 159 Million EUR | 8.09% |
| 2016 Q1 | 147.1 Million EUR | -14.33% |
| 2016 FY | 553.1 Million EUR | -6.19% |
| 2016 Q3 | 149.5 Million EUR | -5.97% |
| 2015 FY | 589.6 Million EUR | 1.31% |
| 2015 Q3 | 130.2 Million EUR | -10.33% |
| 2015 Q4 | 171.7 Million EUR | 31.87% |
| 2015 Q2 | 145.2 Million EUR | 1.89% |
| 2015 Q1 | 142.5 Million EUR | -17.2% |
| 2014 Q4 | 172.1 Million EUR | 18.04% |
| 2014 FY | 582 Million EUR | 16.21% |
| 2014 Q1 | 122.2 Million EUR | -8.33% |
| 2014 Q2 | 141.9 Million EUR | 16.12% |
| 2014 Q3 | 145.8 Million EUR | 2.75% |
| 2013 Q3 | 124.2 Million EUR | -0.32% |
| 2013 FY | 500.8 Million EUR | 13.83% |
| 2013 Q1 | 118.7 Million EUR | 3.16% |
| 2013 Q2 | 124.6 Million EUR | 4.97% |
| 2013 Q4 | 133.3 Million EUR | 7.33% |
| 2012 Q4 | 115.06 Million EUR | 9.9% |
| 2012 FY | 439.96 Million EUR | 4.25% |
| 2012 Q1 | 107.7 Million EUR | -2.2% |
| 2012 Q2 | 112.5 Million EUR | 4.46% |
| 2012 Q3 | 104.7 Million EUR | -6.93% |
| 2011 FY | 422.02 Million EUR | 2.31% |
| 2011 Q4 | 110.12 Million EUR | 11.24% |
| 2011 Q1 | 106.5 Million EUR | 51.75% |
| 2011 Q3 | 99 Million EUR | -6.95% |
| 2011 Q2 | 106.4 Million EUR | -0.09% |
| 2010 Q4 | 70.18 Million EUR | -39.08% |
| 2010 Q3 | 115.2 Million EUR | 2.77% |
| 2010 Q2 | 112.1 Million EUR | -2.52% |
| 2010 FY | 412.48 Million EUR | -6.29% |
| 2010 Q1 | 115 Million EUR | 4.94% |
| 2009 Q4 | 109.59 Million EUR | -2.33% |
| 2009 FY | 440.19 Million EUR | 4.07% |
| 2009 Q2 | 109.1 Million EUR | -0.18% |
| 2009 Q1 | 109.3 Million EUR | 0.0% |
| 2009 Q3 | 112.2 Million EUR | 2.84% |
| 2008 FY | 422.95 Million EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | -100.0% |
| 2004 FY | 217.85 Million EUR | -1.82% |
| 2003 FY | 221.88 Million EUR | -13.95% |
| 2002 FY | 257.85 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BioNTech SE | 3.81 Billion EUR | 82.074% |
| CureVac N.V. | 53.75 Million EUR | -1173.485% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 0.0% |
| BRAIN Biotech AG | 55.33 Million EUR | -1137.192% |
| Formycon AG | 77.69 Million EUR | -781.126% |
| Heidelberg Pharma AG | 9.85 Million EUR | -6843.971% |
| Medigene AG | 6.03 Million EUR | -11245.708% |